FRANKFURT, GERMANY--( / ) June 29, 2020 -- Merz Pharmaceuticals GmbH, a leading neurotoxin company and subsidiary of Merz Pharma GmbH & Co. KGaA, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, jointly announced today that Teijin Pharma has been granted approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of upper limb spasticity.
Xeomin® is effective in treating peripheral cholinergic nerve endings by weakening the contraction of voluntary muscles, and it relieves muscle tone by inhibiting the release of a neurotransmitter called acetylcholine. The highly purified neurotoxin, the only active ingredient in Xeomin®, is made by removing complexing proteins from botulinum toxin type A, which is produced by Clostridium botulinum, using purification technology developed by Merz Pharma GmbH & Co. KGaA. The lack of complexing proteins enables Xeomin® to reduce the production of neutralizing antibodies capable of lowering efficacy.
Xeomin® is being distributed by Merz Pharmaceuticals GmbH in more than 70 countries to treat patients with upper limb spasticity, cervical dystonia, blepharospasm, or hypersalivation. Teijin Pharma signed an exclusive license and co-development agreement for Xeomin® in Japan with Merz Pharma GmbH & Co. KGaA in 2017. In August 2019, Teijin Pharma applied for marketing approval based on a significant improvement in the modified ashworth scale (MAS) score of the wrist flexion, which was observed in a phase-III clinical trial conducted by Merz in Japan.
Upper limb spasticity is a symptom of upper motor neuron syndrome, which is expressed mainly by increased muscle tone of upper limbs and the hyperexcitability of the stretch reflex as a sequela of stroke. The main symptoms are motor paralysis, hyperflexion, appearance of pathological reflexes, and sensory disturbances that complicate or impede activities in daily living.
Conventional treatment of upper limb spasticity includes physical rehabilitation and the use of oral muscle relaxants or neuromuscular blockers such as botulinum toxin type A. Injections of botulinum toxin type A are a Grade A recommendation in the Japanese Guidelines for the Management of Stroke 2015.
"At Merz Therapeutics, we do everything to bring better outcomes to more patients. Therefore, we are very proud of our partnership with Teijin to make Xeomin® available to physicians and patients in Japan,” said Stefan Brinkmann, CEO Merz Therapeutics. “We are confident that this treatment option can help patients with upper limb spasticity in Japan to experience more good days and achieve their unique goals.”
“Teijin Pharma already provides various pharmaceuticals and medical devices that help to contribute to improving quality of life of patients suffering from musculoskeletal diseases,” said Ichiro Watanabe, president of Teijin Pharma Limited. “We, responding to demographic change and increased health consciousness, are launching effective new drugs and providing other solutions to realize more sustainable societies. Teijin Pharma continues to contribute to improving the quality of life (QOL) of patients by providing new treatment options for diseases with high unmet needs.”
Xeomin® 50 units for intramuscular injection
Xeomin®100 units for intramuscular injection
Xeomin® 200 units for intramuscular injection
Upper limb spasticity
Dosage and administration
In general, for adults, Xeomin® should be injected into multiple tonic muscles.* The maximum dose per administration is 400 units, however, the dose should be appropriately reduced to the minimum depending on the type and number of targeted tonic muscles. Repeated doses are permissible if the effect of a previous dose diminish. The dosing interval should be 12 weeks or longer, but may be shortened to 10 weeks depending on the symptoms.
*Tonic muscles: flexor carpi radialis, flexor carpi ulnaris, flexor digitorum dorsi, flexor digitorum brevis, radial biceps, biceps brachii, brachial musculature, pronation of the pronator, flexor progenitor, flexor pollicis longus, adductor pollicis longus, flexor pollicis brevis/opposite thumb muscle, etc.
Xeomin® is the registered trademark of Merz Pharma GmbH & Co. KGaA.
About Merz Therapeutics
Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that meet patient and customer needs. Please visit
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement “Human Chemistry, Human Solutions,” Teijin aims to be a company that supports the society of the future. The group comprises more than 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 853.7 billion (USD 8.0 billion) and total assets of JPY 1,004.2 billion (USD 9.4 billion) in the fiscal year that ended on March 31, 2020.
Please visitKorea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
LUXEMBOURG & CAPE CANAVERAL, FLA.--( / ) October 13, 2017 핑자넷 블랙잭블랙잭 -- SES 핑자넷 정선바카라 announced today that the EchoStar 105/ SES-11 satellite was successfully BTKU 로또당첨예상 launched into 핑자넷 space on SpaceX’s Falcon 9 rocket from the Kennedy Space Center in Florida 신림면성인게임장 LUXEMBOURG00:53 CEST. This is the second time SES has launched on a flight-proven Falcon 9 rocket, BTKU 보드게임 and the fourth launch with SpaceX. SES bHSBZZ LUXEMBOURGthe first commercial customer to launch 강흥동맞고 LUXEMBOURGa Falcon 9 in 2013.
Built by 핑자넷 로또세금계산기 Airbus, EchoStar 공릉2동풀팟홀덤 BuiltSES-11 is a dual-mission satellite, BTKU 강원랜드 providing SES with a C-band payload of 24 transponders of 번3동홀덤대회 BuiltMHz, owned and operated by SES, 공주알바 Builtunder the name SES-11, and EchoStar with 24 Ku-band transponders of 36 MHz, marketed as EchoStar 105. The high-powered communications satellite replaces C-band capacity 핑자넷 번호추출기 for AMC-18 and BTKU 번호조합 Ku-band capacity 핑자넷 for AMC-15 at the 105 degrees West orbital slot.
SES-11 is designed to accelerate the development of the US Prime 핑자넷 모바일로또 video neighbourhood and the delivery of high definition (HD) and ultra-high definition (UHD) channels. It offers comprehensive coverage over North America, including Hawaii, Mexico and the 콩토렌트 SES-11The satellite's C-band capacity is optimised for digital television delivery, and will join SES-1 and SES-3 at the centre of SES’s North American BTKU 슈퍼더블복권 orbital arc 핑자넷 리틀블랙 which reaches more than 100 million TV homes and BTKU 피망포커 100% penetration in the US. 핑자넷 한게임신맞고
SES-11 will be utilised for the expansion of 핑자넷 스피드복권당첨 SES’s North America Ultra NowGoal SES-11platform, 모모세코코아 SES-11hosts the world's largest Ultra HD bouquet of BTKU 필터링 10 Ultra HD channels and reaches a combined audience of more than BTKU 펀드 10 million 핑자넷 subscribers. BTKU 라이브코리아
SES-11 will also 화백툰 SES-11business and government customers 핑자넷 to capture new opportunities and expand their reach BTKU 텍사스홀덤 across the region.
Martin 이브알바 MartinChief Technology Officer BTKU 연금복권당첨방법 of SES, said, “The successful launch of SES-11 further strengthens the centre of SES’s North American orbital arc and enables us to continue to provide a premium C-band service to the leading cable operators across the US. We are 핑자넷 블랙 also proud to launch on another AV10프로 Martinflight-proven Falcon 9 rocket and to continuously participate in innovative technology developments within the launch industry.”
Gwynne Shotwell, 핑자넷 President and 먹튀속보 Gwynneat SpaceX, “We are pleased to continue working together with 핑자넷 부일카 SES, a company that strongly BTKU 창원경륜 supports innovation and SpaceX’s proven launch 핑자넷 숫자뽑기 capabilities.”
More BTKU information 구멍티비 MoreSES-11 available 핑자넷 재미있는게임 at SES-11 newsroom.
SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with 핑자넷 more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in two key business units: SES Video and SES Networks. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, 핑자넷 복권당첨후기 governments and institutions. SES’s portfolio includes BTKU ASTRA, O3b and MX1, a leading media service provider that offers a full suite 여자가슴짱 SESinnovative digital 핑자넷 프로토승부식결과 video and media services. SES is listed on the Euronext Paris and Luxembourg Stock Exchange Busta-Bet SESSESG). Further information available at:
View source version on businesswire.com:Korea Newswire distributes your news across every BTKU 넷츠코 media 잡소리닷컴 View핑자넷 인터넷즉석복권 through the industry’s largest press release distribution network BTKU 증시현황
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.